Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Double-dummy, Placebo-controlled 26-week Dose-response Study of Rivoglitazone HCl (CS-011) With Active Comparator (Pioglitazone HCl) in Subjects With Type 2 Diabetes

NCT00143520 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT00143520
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00143520 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Double-dummy, Placebo-controlled 26-week Dose-response Study of Rivoglitazone HCl (CS-011) With Active Comparator (Pioglitazone HCl) in Subjects With Type 2 Diabetes
Lead sponsor
Daiichi Sankyo
Phase
Phase 2/3
Overall status
Completed
Start date
December 31, 2004
Completion date
December 31, 2005
Enrollment
441 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes